Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
220 participants
OBSERVATIONAL
2012-10-18
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition to the procedures for the patient's routine clinical visit, the patients will be invited to answer a series of questionnaires and donate 20ml blood sample. Patients will be asked to attend 3 times over 24 weeks
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Imaging Markers for Rheumatoid Arthritis
NCT01773681
Initial Validation of PROMIS Physical Function/Disability Scales in Rheumatoid Arthritis (RA)
NCT00786227
Study Evaluating Health Related Utility in Rheumatoid Arthritis
NCT00471874
Evaluation of a Therapeutic Education Program on Self-image in Patients With Chronic Inflammatory Rheumatic Diseases
NCT07170826
Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica
NCT05542316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1A
Early phase, requiring change in treatment
No interventions assigned to this group
Group 2
Established phase, stable treatment
No interventions assigned to this group
Group 2A
Established phase, requiring a change in treatment
No interventions assigned to this group
Group 1
Early phase, stable treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or Female, aged 18 years or above.
* Written confirmed diagnosed of rheumatoid arthritis
Exclusion Criteria
* Multiple sclerosis
* Motor neurone disease
* Parkinson's disease
* Alzheimer's disease
* Depression or anxiety disorders as identified using the Patient depression screening questions from the patient health questionnaire 9 (PHQ9).
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Taylor, FRCP, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nuffield Orthopaedic Centre
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010930
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.